Peripheral expression of long non-coding RNAs in bipolar patients

Sayad, Arezou; Taheri, Mohammad; Fallah, Hossein; Oskooei, Vahid Kholghi; Ghafouri‐Fard, Soudeh

doi:10.1016/j.jad.2019.02.034

Cited by 21 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two previously appreciated mechanisms for the observed sex-based differences in human diseases are gonadal sex hormones or the sex chromosomes 28 . The current study and similar studies in neuropsychiatric disorders 29 provide preliminary evidences for contribution of lncRNAs in this process. However, further studies are required to appraise whether this effect is exerted through interaction with the previously appraised mechanisms or is performed independently.…”

Section: Discussionsupporting

confidence: 65%

Sex-specific up-regulation of lncRNAs in peripheral blood of patients with schizophrenia

Fallah

Azari

Neishabouri

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

Schizophrenia as a common disabling psychiatric disorder has been associated with dysregulation of several genes and pathways among them are those being regulated by long non-coding RNAs (lncRNAs). Based on the acknowledged roles of lncRNAs in neurodevelopment, in the current study, we assessed expression of six lncRNAs namely HOXA-AS 2, Linc-ROR , MALAT1 , MEG3 , SPRY4-IT1 and UCA1 in peripheral blood of 60 patients with schizophrenia and 60 healthy subjects. HOXA-AS2 , Linc-ROR , MEG3 , SPRY4-IT1 and UCA1 levels were significantly higher in total patients compared with total controls. However, when evaluating expression of genes in sex-based subgroups, the differences in the expression of these lncRNAs were significant only among females. Assessment of partial correlation between expression of lncRNAs and age of study participants after controlling the effect of sex, revealed significant correlations for HOXA-AS2 , MALAT1 and UCA1 in both patients and controls. Besides, expressions of Linc-ROR and SPRY4-IT1 were correlated with age only in patients. Significant pairwise correlations were recognized between expression levels of lncRNAs in both patients with schizophrenia and controls. Based on the area under curve (AUC) values, SPRY4-IT1 had the best performance in differentiation of female patients with schizophrenia from female controls (AUC = 0.85, P < 0.0001). Combination of Linc-ROR , MEG3 , SPRY4-IT1 and UCA1 expression levels could differentiate female patients with 95.2% sensitivity, 76.9% specificity and diagnostic power of 0.88 (P < 0.0001). The current study suggests the presence of a sex-based dysregulation of lncRNAs in patients with schizophrenia and their possible application as diagnostic biomarkers.

show abstract

Section: Discussionsupporting

confidence: 65%

Sex-specific up-regulation of lncRNAs in peripheral blood of patients with schizophrenia

Fallah

Azari

Neishabouri

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“… 89 Several alterations in the levels of microRNAs and long noncoding RNAs have been detected in BD samples, some of which have been validated by independent studies. 90 , 91 Recent studies have also suggested that noncoding RNAs may function as clinically relevant peripheral biomarkers when assessed from neuron-derived extracellular vesicles, which are currently being investigated in BD patients. 92 , 93 Altogether, these studies suggest an important role for noncoding RNAs in BD pathophysiology, and also their potential as an important diagnostic and prognostic tool.…”

Section: Genetics and Epigenetics Of Bipolar Disordermentioning

confidence: 99%

Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings

Scaini

Valvassori

Diaz

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

Bipolar disorder (BD) is a chronic mental illness characterized by changes in mood that alternate between mania and hypomania or between depression and mixed states, often associated with functional impairment. Although effective pharmacological and non-pharmacological treatments are available, several patients with BD remain symptomatic. The advance in the understanding of the neurobiology underlying BD could help in the identification of new therapeutic targets as well as biomarkers for early detection, prognosis, and response to treatment in BD. In this review, we discuss genetic, epigenetic, molecular, physiological and neuroimaging findings associated with the neurobiology of BD. Despite the advances in the pathophysiological knowledge of BD, the diagnosis and management of the disease are still essentially clinical. Given the complexity of the brain and the close relationship between environmental exposure and brain function, initiatives that incorporate genetic, epigenetic, molecular, physiological, clinical, environmental data, and brain imaging are necessary to produce information that can be translated into prevention and better outcomes for patients with BD.

show abstract

“…The expression of PANDA is induced by the apoptotic pathway protein P53, which regulates, and is regulated by, inflammatory pathways [105]. This same study also reported increased levels of the lncRNA Taurine Up-Regulated 1 (TUG1) [102], a competing endogenous RNA that acts as a molecular sponge for the inflammation associated miRNA, miR-29b [106,107]. Whilst these findings are in peripheral tissue, changes inflammation-related lncRNA are also seen in the CNS of subjects with BD.…”

Section: Long Non-coding Rna In Mood Disordersmentioning

confidence: 96%

“…A number of studies have reported changed levels of lncRNA in patients with BD [102][103][104]. Amongst these lncRNA, several have been identified that target pathways involved in inflammation-related processes.…”

Section: Long Non-coding Rna In Mood Disordersmentioning

confidence: 99%

“…It is notable that this lncRNA controls the expression of the cytokine IFNG and the decreased expression of IFNG-AS1 in BD correlated with a decreasing IFNG expression and with a corresponding decrease in the levels of the pro-inflammatory cytokine IL1B [103], suggesting a functional impact of changed IFNG-AS1 levels. Similarly, Promoter of CDKN1A Antisense DNA Damage Activated RNA (PANDA), a DNA-damage activated lncRNA is also increased in blood from patients with BD [102]. The expression of PANDA is induced by the apoptotic pathway protein P53, which regulates, and is regulated by, inflammatory pathways [105].…”

Section: Long Non-coding Rna In Mood Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

Gibbons

Sundram

Dean

2020

ncRNA

View full text Add to dashboard Cite

The similarities between the depressive symptoms of Major Depressive Disorders (MDD) and Bipolar Disorders (BD) suggest these disorders have some commonality in their molecular pathophysiologies, which is not apparent from the risk genes shared between MDD and BD. This is significant, given the growing literature suggesting that changes in non-coding RNA may be important in both MDD and BD, because they are causing dysfunctions in the control of biochemical pathways that are affected in both disorders. Therefore, understanding the changes in non-coding RNA in MDD and BD will lead to a better understanding of how and why these disorders develop. Furthermore, as a significant number of individuals suffering with MDD and BD do not respond to medication, identifying non-coding RNA that are altered by the drugs used to treat these disorders offer the potential to identify biomarkers that could predict medication response. Such biomarkers offer the potential to quickly identify patients who are unlikely to respond to traditional medications so clinicians can refocus treatment strategies to ensure more effective outcomes for the patient. This review will focus on the evidence supporting the involvement of non-coding RNA in MDD and BD and their potential use as biomarkers for treatment response.

show abstract

Peripheral expression of long non-coding RNAs in bipolar patients

Cited by 21 publications

References 15 publications

Sex-specific up-regulation of lncRNAs in peripheral blood of patients with schizophrenia

Sex-specific up-regulation of lncRNAs in peripheral blood of patients with schizophrenia

Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

Contact Info

Product

Resources

About